Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Phase 2

Recruiting

Conditions: Thymoma

Interventions: Radiation: Radiotherapy
Drug: Concurrent chemotherapy
Drug: Methylprednisolone

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 45

Registration Number: NCT06730308

Locations: 🇨🇳
Sun yat-sen University Cancer Center, Guanzhou, Guangdong, China

Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness

Early Phase 1

Not yet recruiting

Conditions: Sudden Deafness
Sensorineural Hearing Loss

Interventions: Drug: Methylprednisolone
Biological: autologous blood monocyte vesicles
Biological: autologous blood monocyte vesicles and Methylprednisolone

First Posted Date: 2024-11-27

Last Posted Date: 2024-11-27

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 60

Registration Number: NCT06707389

The Role of Olive Oil in the Treatment of Covid-19 Pneumonia

Completed

Conditions: COVID-19 Pneumonia
Nutrition, Healthy

Interventions: Dietary Supplement: Olive Oil
Drug: Methylprednisolone

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Giresun University

Target Recruit Count: 130

Registration Number: NCT06677658

Locations: 🇹🇷
Giresun Training and Research Hospital, Gi̇resun, Turkey

Corticosteroids for Post-Extubation Dysphagia

Phase 2

Recruiting

Conditions: Dysphagia
Laryngeal Edema

Interventions: Drug: Methylprednisolone
Drug: Normal Saline

First Posted Date: 2024-11-01

Last Posted Date: 2024-11-19

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 80

Registration Number: NCT06670521

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States

The Effect of Methylprednisolone Administration on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group

Phase 4

Not yet recruiting

Conditions: Sugammadex Reversal Time

Interventions: Other: Saline (NaCl 0,9 %) (placebo)
Drug: methylprednisolone

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Konya City Hospital

Target Recruit Count: 80

Registration Number: NCT06623370

Intracoronary Administration of Glucocorticoids as a Treatment Method for No-Glucocorticoid Treatment for No-Reflow in STEMI

Phase 2

Completed

Conditions: Ischemia-reperfusion Injury
No-reflow

Interventions: Drug: Methylprednisolone

First Posted Date: 2024-08-14

Last Posted Date: 2024-08-14

Lead Sponsor: Amosov National Institute of Cardiovascular Surgery

Target Recruit Count: 10

Registration Number: NCT06552442

Locations: 🇺🇦
Amosov National Institute of cardiovascular surgery, Kyiv, Amosov Street, 6, Ukraine

A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome

Phase 2

Recruiting

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: Methylprednisolone
Drug: Dexamethasone
Drug: Hydrocortisone

First Posted Date: 2024-07-11

Last Posted Date: 2024-12-16

Lead Sponsor: Fayoum University

Target Recruit Count: 300

Registration Number: NCT06496997

Locations: 🇪🇬
Fayoum University, Fayoum, Egypt

TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Phase 4

Not yet recruiting

Conditions: Rejection; Transplant, Pancreas
Rejection; Transplant, Kidney

Interventions: Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: University of Sydney

Target Recruit Count: 540

Registration Number: NCT06474273

Locations: 🇨🇦
Transplant Manitoba, adult, Winnipeg, Manitoba, Canada
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Queensland Children's Hospital, South Brisbane, Queensland, Australia

and more 19 locations